RhAPPcast: Unpacking the Differences: IL-23 Inhibitors in Focus
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
RhAPPcast: Unpacking the Differences: IL-23 Inhibitors in Focus
-
Narrated by:
-
Written by:
About this listen
In this episode of RhAPPcast, host Amanda Mixon, President of RhAPP, is joined by rheumatology PA Audrey Gibson for an in-depth discussion on IL-23 inhibitors and what differentiates them in real-world rheumatology practice. The conversation reviews the IL-23/Th17 pathway, current approved IL-23 inhibitors for psoriatic arthritis, and key considerations around efficacy, safety, durability, and patient selection, including comorbid psoriasis and inflammatory bowel disease. Designed for rheumatology APPs, this episode also explores practical expectations for treatment response, emerging clinical trial data, and how IL-23 inhibitors fit into a domain-based approach to managing psoriatic disease.
No reviews yet